GlassScriptPhysician profile
Ehsaan Akhtar
NPI 1710255591
$8,017.31
in general payments reported to CMS, 2019-2025
32 companies · $871 in 2025
The $871 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $268 · 2021: $1,219 · 2022: $1,626 · 2023: $1,882 · 2024: $1,836 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,304 · Travel and Lodging: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,303.73 |
| Travel and Lodging | $1,286.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,869.83 | 2020-2024 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,131.91 | 2020-2024 | Xifaxan, Trulance |
| Boston Scientific Corporation | $947.33 | 2019-2024 | |
| Celgene Corporation | $692.92 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $584.48 | 2022-2024 | Stelara |
| Steris Corporation | $551.04 | 2025 | |
| Olympus Corporation of The Americas | $333.62 | 2024-2025 | Single Use Electrosurgical Knife Kd-655, Disposable Distal Attachment, Olympus |
| Nestle Healthcare Nutrition INC. | $227.60 | 2021-2023 | |
| Ardelyx, INC. | $190.84 | 2022-2023 | Ibsrela |
| Pfizer INC. | $159.68 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $136.73 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $121.36 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.46 | 2021-2023 | Entyvio |
| Intercept Pharmaceuticals, INC. | $114.28 | 2022-2025 | Ocaliva |
| Regeneron Pharmaceuticals, INC. | $107.14 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $106.89 | 2021-2023 | Xarelto |
| Olympus America INC. | $79.71 | 2024 | Visiglide, Endoclot Phs |
| Merck Sharp & Dohme LLC | $78.31 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $56.91 | 2019 | |
| Redhill Biopharma INC. | $53.16 | 2020-2022 | |
| Micro-Tech Endoscopy USA, INC. | $50.33 | 2020-2024 | Eyemax |
| Gilead Sciences, INC. | $49.14 | 2021 | |
| Alfasigma USA, INC. | $43.62 | 2020 | |
| Daiichi Sankyo INC. | $31.58 | 2020-2024 | Injectafer |
| Fresenius Kabi USA, LLC | $28.75 | 2024 | Idacio |
| Qol Medical, LLC | $28.02 | 2024 | Sucraid |
| Lilly USA, LLC | $26.82 | 2024 | Omvoh |
| Genzyme Corporation | $25.39 | 2022 | |
| Madrigal Pharmaceuticals | $23.44 | 2024 | Resmetirom |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.01 | 2023 | Cyltezo |
| Regeneron Healthcare Solutions, INC. | $13.34 | 2024 | Dupixent |
| Braintree Laboratories, INC. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ehsaan Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.